comparemela.com

Latest Breaking News On - L dopa - Page 2 : comparemela.com

Novel Levodopa Delivery System Promises Continuous Dosing

Called DopaFuse, the experimental device is designed to deliver the levodopa and carbidopa into the mouth through a micropump within a wearable retainer.

United statesNew yorkStuart isaacsonBoca ratonAaronl ellenbogenC warren olanowAmerican academy of neurologyMovement disorders centerIcahn school of medicine at mount sinaiEmerging scienceAmerican academyIcahn schoolMount sinaiBeaumont hospitalFarmington hillsParkinsons disease

Novel Continuous Infusion System Promising for Parkinson s

Continuous infusion strategies have long been sought as a method to preserve levodopa efficacy.

United statesAaron ellenbogenAlbertoj espayMovement disordersGardner family centerUniversity of cincinnatiAmerican academy of neurologyUniversity of miamiAmerican academyUnited parkinsonDisease rating scalePatient global impressionClinical global impressionIhtsham ul haqKyowa kirinParkinsons disease

Parkinson s Disease: Focus on Hallucinations

Patients often hide their hallucinations, which are associated with poor long-term outcomes and a reduced quality of life.

United statesFrance generalHayet salhiHenri mondor university hospital in crHenri mondor university hospitalParkinsons diseaseAnxiety disorderQuality of lifeEalth related quality of lifeDopamine agonistPractice managementPain managementPain managementAnticholinergic drugNeuroleptic drugsAtypical antipsychotics

ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split

Acorda Therapeutics, Inc.

Johnp kelleyTierney saccavinoExchange commissionEgan jones coNy acorda therapeutics incInstitutional shareholder servicesAcorda therapeuticsShareholder servicesGlass lewisReverse stock splitSpecial meetingStockholders can voteReverse splitExtended release tabletsNasdaq global select marketForward looking statement

Acorda Therapeutics Announces $16 5M Award and Royalty/Supply Relief in AMPYRA Arbitration Case

Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes.

Tierney saccavinoRon cohenExchange commissionNy acorda therapeutics incAcorda therapeuticsAmerican arbitration associationExtended release tabletsNasdaq global select marketForward looking statementLife sciences4 aminopyridineFinancial riskL dopaRoyalty payment

vimarsana © 2020. All Rights Reserved.